{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T01:08:35Z","timestamp":1779239315217,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Three-year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals","award":["SHDC2024CRI088"],"award-info":[{"award-number":["SHDC2024CRI088"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01380-7","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:33:30Z","timestamp":1774582410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk assessment of secondary primary malignancies: results from two large prospective European cohorts"],"prefix":"10.1038","volume":"10","author":[{"given":"Jiajing","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youlutuziayi","family":"Rixiati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunjun","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengshi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"1380_CR1","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1002\/cncr.30164","volume":"122","author":"N Donin","year":"2016","unstructured":"Donin, N. et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 122, 3075\u20133086 (2016).","journal-title":"Cancer"},{"key":"1380_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2020.11.042","volume":"145","author":"N Waespe","year":"2021","unstructured":"Waespe, N. et al. Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer\u2014a national cohort study. Eur. J. Cancer 145, 71\u201380 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1380_CR3","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s10147-019-01430-0","volume":"24","author":"JL Wei","year":"2019","unstructured":"Wei, J. L., Jiang, Y. Z. & Shao, Z. M. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study. Int. J. Clin. Oncol. 24, 934\u2013940 (2019).","journal-title":"Int. J. Clin. Oncol."},{"key":"1380_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1053\/j.semnuclmed.2024.05.002","volume":"54","author":"NC Nguyen","year":"2024","unstructured":"Nguyen, N. C., Anigati, E. M., Desai, N. B. & Oz, O. K. Radioactive iodine therapy in differentiated thyroid cancer: an update on dose recommendations and risk of secondary primary malignancies. Semin. Nucl. Med. 54, 488\u2013496 (2024).","journal-title":"Semin. Nucl. Med."},{"key":"1380_CR5","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix, T. et al. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5517 lymphoma and myeloma patients. Clin. Cancer Res. 30, 4690\u20134700 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1380_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.120643","volume":"355","author":"JX Wang","year":"2026","unstructured":"Wang, J. X., Zhang, M. X., Yu, C. H., Wang, S. J. & Zhang, H. Targeting DNA damage: a natural product-based strategy for inhibiting cancer progression. J. Ethnopharmacol. 355, 120643 (2026).","journal-title":"J. Ethnopharmacol."},{"key":"1380_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.tips.2024.01.009","volume":"45","author":"S Bhatia","year":"2024","unstructured":"Bhatia, S., Khanna, K. K. & Duijf, P. H. G. Targeting chromosomal instability and aneuploidy in cancer. Trends Pharm. Sci. 45, 210\u2013224 (2024).","journal-title":"Trends Pharm. Sci."},{"key":"1380_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.annonc.2024.02.008","volume":"35","author":"RS Laskar","year":"2024","unstructured":"Laskar, R. S. et al. Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer. Ann. Oncol. 35, 523\u2013536 (2024).","journal-title":"Ann. Oncol."},{"key":"1380_CR9","doi-asserted-by":"publisher","first-page":"n2233","DOI":"10.1136\/bmj.n2233","volume":"375","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova, V. W. et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ 375, n2233 (2021).","journal-title":"BMJ"},{"key":"1380_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jso.2930410205","volume":"41","author":"H Kuwano","year":"1989","unstructured":"Kuwano, H. et al. Occurrence of esophageal carcinoma after gastrectomy. J. Surg. Oncol. 41, 77\u201380 (1989).","journal-title":"J. Surg. Oncol."},{"key":"1380_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-25346-0","volume":"15","author":"J He","year":"2025","unstructured":"He, J., Luo, B., Liu, H., Cao, D. & Gong, W. Analysis of the risk of metachronous colorectal cancer and long-term prognosis in patients following gastrectomy for gastric cancer. Sci. Rep. 15, 41518 (2025).","journal-title":"Sci. Rep."},{"key":"1380_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56408-4","volume":"14","author":"L Jin","year":"2024","unstructured":"Jin, L., Su, X., Li, W., Wu, J. & Zhang, H. Incidence, risk and prognosis of second primary malignancy of patients with gastric adenocarcinoma. Sci. Rep. 14, 5766 (2024).","journal-title":"Sci. Rep."},{"key":"1380_CR13","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.21037\/tcr-20-1105","volume":"9","author":"S Li","year":"2020","unstructured":"Li, S., Luo, Y., Hou, Q., Chu, H. & Zheng, H. Incidence features of second primary malignancy among gastric cancer survivors, 1992-2012. Transl. Cancer Res. 9, 7001\u20137011 (2020).","journal-title":"Transl. Cancer Res."},{"key":"1380_CR14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s10120-015-0482-3","volume":"19","author":"SC Chen","year":"2016","unstructured":"Chen, S. C. et al. Second primary malignancy risk among patients with gastric cancer: a nationwide population-based study in Taiwan. Gastric Cancer 19, 490\u2013497 (2016).","journal-title":"Gastric Cancer"},{"key":"1380_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68776-y","volume":"14","author":"L Song","year":"2024","unstructured":"Song, L. et al. Analyzing risk factors for second malignancies in early gastric carcinoma from the SEER database. Sci. Rep. 14, 17761 (2024).","journal-title":"Sci. Rep."},{"key":"1380_CR16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.1991.03460100089030","volume":"265","author":"WJ Blot","year":"1991","unstructured":"Blot, W. J., Devesa, S. S., Kneller, R. W. & Fraumeni, J. F. Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265, 1287\u20131289 (1991).","journal-title":"JAMA"},{"key":"1380_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0140-6736(75)90498-5","volume":"2","author":"P Correa","year":"1975","unstructured":"Correa, P., Haenszel, W., Cuello, C., Tannenbaum, S. & Archer, M. A model for gastric cancer epidemiology. Lancet 2, 58\u201360 (1975).","journal-title":"Lancet"},{"key":"1380_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/1055-9965.EPI-10-0843","volume":"20","author":"ML Slattery","year":"2011","unstructured":"Slattery, M. L., Herrick, J. S., Lundgreen, A. & Wolff, R. K. Genetic variation in the TGF-beta signaling pathway and colon and rectal cancer risk. Cancer Epidemiol. Biomark. Prev. 20, 57\u201369 (2011).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"1380_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02363-1","volume":"24","author":"X Wu","year":"2025","unstructured":"Wu, X., Que, H., Li, Q. & Wei, X. Wnt\/beta-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy. Mol. Cancer 24, 171 (2025).","journal-title":"Mol. Cancer"},{"key":"1380_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/0008-5472.CAN-19-1161","volume":"80","author":"S Ferrandon","year":"2020","unstructured":"Ferrandon, S. et al. CoA synthase (COASY) mediates radiation resistance via PI3K signaling in rectal cancer. Cancer Res. 80, 334\u2013346 (2020).","journal-title":"Cancer Res."},{"key":"1380_CR21","doi-asserted-by":"publisher","unstructured":"Chmielewski, P. P., Strzelec, B. & Rudno-Rudzinska, J. Wnt signaling and circular RNAs in esophageal and gastric cancers: opportunities for early detection and targeted therapy. J. Clin. Med. 14, https:\/\/doi.org\/10.3390\/jcm14134805 (2025).","DOI":"10.3390\/jcm14134805"},{"key":"1380_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas, N.","year":"2012","unstructured":"Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","journal-title":"Nature"},{"key":"1380_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research, N.","year":"2014","unstructured":"Cancer Genome Atlas Research, N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202\u2013209 (2014).","journal-title":"Nature"},{"key":"1380_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbcan.2019.05.003","volume":"1872","author":"R Caspa Gokulan","year":"2019","unstructured":"Caspa Gokulan, R., Garcia-Buitrago, M. T. & Zaika, A. I. From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma. Biochim. Biophys. Acta Rev. Cancer 1872, 37\u201348 (2019).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1380_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tranon.2016.10.003","volume":"10","author":"Z Liu","year":"2017","unstructured":"Liu, Z., Sun, Q. & Wang, X. PLK1, a potential target for cancer therapy. Transl. Oncol. 10, 22\u201332 (2017).","journal-title":"Transl. Oncol."},{"key":"1380_CR26","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1158\/0008-5472.CAN-20-1377","volume":"81","author":"L Gheghiani","year":"2021","unstructured":"Gheghiani, L. et al. PLK1 induces chromosomal instability and overrides cell-cycle checkpoints to drive tumorigenesis. Cancer Res. 81, 1293\u20131307 (2021).","journal-title":"Cancer Res."},{"key":"1380_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114747","volume":"193","author":"S Iliaki","year":"2021","unstructured":"Iliaki, S., Beyaert, R. & Afonina, I. S. Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochem. Pharm. 193, 114747 (2021).","journal-title":"Biochem. Pharm."},{"key":"1380_CR28","doi-asserted-by":"publisher","first-page":"e1011309","DOI":"10.1371\/journal.pgen.1011309","volume":"20","author":"Y Kong","year":"2024","unstructured":"Kong, Y. et al. Single-cell analysis identifies PLK1 as a driver of immunosuppressive tumor microenvironment in LUAD. PLoS Genet. 20, e1011309 (2024).","journal-title":"PLoS Genet."},{"key":"1380_CR29","doi-asserted-by":"publisher","first-page":"37633","DOI":"10.18632\/oncotarget.16839","volume":"8","author":"L Zhu","year":"2017","unstructured":"Zhu, L. et al. Involvement of Polo-like kinase 1 (Plk1) in quiescence regulation of cancer stem-like cells of the gastric cancer cell lines. Oncotarget 8, 37633\u201337645 (2017).","journal-title":"Oncotarget"},{"key":"1380_CR30","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.CD-12-0595","volume":"3","author":"J Tan","year":"2013","unstructured":"Tan, J. et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov. 3, 1156\u20131171 (2013).","journal-title":"Cancer Discov."},{"key":"1380_CR31","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1158\/0008-5472.CAN-11-3893","volume":"72","author":"AM Dulak","year":"2012","unstructured":"Dulak, A. M. et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 72, 4383\u20134393 (2012).","journal-title":"Cancer Res."},{"key":"1380_CR32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu, R. et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449\u2013456 (2015).","journal-title":"Nat. Med."},{"key":"1380_CR33","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/0016-5085(92)90022-Q","volume":"103","author":"F Imazeki","year":"1992","unstructured":"Imazeki, F., Omata, M., Nose, H., Ohto, M. & Isono, K. p53 gene mutations in gastric and esophageal cancers. Gastroenterology 103, 892\u2013896 (1992).","journal-title":"Gastroenterology"},{"key":"1380_CR34","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-018-0022-x","volume":"24","author":"GS Wong","year":"2018","unstructured":"Wong, G. S. et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat. Med. 24, 968\u2013977 (2018).","journal-title":"Nat. Med."},{"key":"1380_CR35","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.annonc.2022.08.001","volume":"33","author":"JE Augustin","year":"2022","unstructured":"Augustin, J. E., Soussan, P. & Bass, A. J. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Ann. Oncol. 33, 1134\u20131148 (2022).","journal-title":"Ann. Oncol."},{"key":"1380_CR36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"1380_CR37","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang, M. et al. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm. Sin. B 11, 2983\u20132994 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"1380_CR38","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-10-0821","volume":"16","author":"SA Martin","year":"2010","unstructured":"Martin, S. A., Lord, C. J. & Ashworth, A. Therapeutic targeting of the DNA mismatch repair pathway. Clin. Cancer Res. 16, 5107\u20135113 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1380_CR39","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10120-024-01523-4","volume":"27","author":"A Ooki","year":"2024","unstructured":"Ooki, A., Osumi, H., Yoshino, K. & Yamaguchi, K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair. Gastric Cancer 27, 907\u2013931 (2024).","journal-title":"Gastric Cancer"},{"key":"1380_CR40","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1200\/JCO.2016.66.6826","volume":"34","author":"N de Rosa","year":"2016","unstructured":"de Rosa, N. et al. DNA mismatch repair deficiency in rectal cancer: benchmarking its impact on prognosis, neoadjuvant response prediction, and clinical cancer genetics. J. Clin. Oncol. 34, 3039\u20133046 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1380_CR41","first-page":"e82939","volume":"17","author":"CE Bonilla","year":"2025","unstructured":"Bonilla, C. E., Avila-Rodriguez, V., Jimenez-Vasquez, P., Vargas Diaz, M. J. & Guerrero, S. Mismatch repair deficiency in esophageal squamous cell carcinoma: an underrecognized biomarker for immunotherapy response. Cureus 17, e82939 (2025).","journal-title":"Cureus"},{"key":"1380_CR42","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/jgc4.1584","volume":"31","author":"K Tlusty","year":"2022","unstructured":"Tlusty, K., Jackson, M., Riley, B. & Blase, T. Effects of diet education on empowerment for individuals who have an increased risk of developing breast or colon cancer: a pilot study. J. Genet. Couns. 31, 1138\u20131147 (2022).","journal-title":"J. Genet. Couns."},{"key":"1380_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12094-020-02388-6","volume":"23","author":"G Baldelli","year":"2021","unstructured":"Baldelli, G. et al. The effects of human sera conditioned by high-intensity exercise sessions and training on the tumorigenic potential of cancer cells. Clin. Transl. Oncol. 23, 22\u201334 (2021).","journal-title":"Clin. Transl. Oncol."},{"key":"1380_CR44","doi-asserted-by":"publisher","unstructured":"Diez de Los Rios de la Serna, C., Fernandez-Ortega, P. & Lluch-Canut, T. Lifestyle behavior interventions for preventing cancer in adults with inherited cancer syndromes: systematic review. Int. J. Environ. Res. Public Health 19, https:\/\/doi.org\/10.3390\/ijerph192114098 (2022).","DOI":"10.3390\/ijerph192114098"},{"key":"1380_CR45","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.21037\/jgo-2025-200","volume":"16","author":"W Liu","year":"2025","unstructured":"Liu, W., Liu, Y., Chen, H. W., Peng, Z. Z. & Liao, K. Global burden of gastric cancer attributed to high-salt diets: spatiotemporal trends and socio-demographic inequalities from 1990 to 2021. J. Gastrointest. Oncol. 16, 1403\u20131419 (2025).","journal-title":"J. Gastrointest. Oncol."},{"key":"1380_CR46","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar, R. et al. Gastric cancer. Lancet 405, 2087\u20132102 (2025).","journal-title":"Lancet"},{"key":"1380_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30098-w","volume":"13","author":"A Choudhury","year":"2022","unstructured":"Choudhury, A. et al. Meta-analysis of sub-Saharan African studies provides insights into genetic architecture of lipid traits. Nat. Commun. 13, 2578 (2022).","journal-title":"Nat. Commun."},{"key":"1380_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jclinepi.2014.09.005","volume":"68","author":"JF Cohen","year":"2015","unstructured":"Cohen, J. F. et al. Cochran\u2019s Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy. J. Clin. Epidemiol. 68, 299\u2013306 (2015).","journal-title":"J. Clin. Epidemiol."},{"key":"1380_CR49","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50, 693\u2013698 (2018).","journal-title":"Nat. Genet."},{"key":"1380_CR50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi, S., Rucker, G. & Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. Evid. Based Ment. Health 22, 153\u2013160 (2019).","journal-title":"Evid. Based Ment. Health"},{"key":"1380_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01277-x","volume":"15","author":"SA Beer","year":"2025","unstructured":"Beer, S. A. et al. Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy. Blood Cancer J. 15, 62 (2025).","journal-title":"Blood Cancer J."},{"key":"1380_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03096-y","volume":"21","author":"H Gao","year":"2023","unstructured":"Gao, H., Zheng, S., Yuan, X., Xie, J. & Xu, L. Causal association between inflammatory bowel disease and 32 site-specific extracolonic cancers: a Mendelian randomization study. BMC Med. 21, 389 (2023).","journal-title":"BMC Med."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01380-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:49:02Z","timestamp":1779238142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01380-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01380-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}